{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:39:54Z","timestamp":1765885194819,"version":"3.48.0"},"reference-count":38,"publisher":"BMJ","issue":"2","funder":[{"name":"The University of Sydney Faculty of Pharmacy summer student scholarship program provided funding for Swestika Swandari\u2019s work on this study."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,11,28]]},"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate patterns of industry-sponsored educational events that focus on specific health conditions for which there are concerns about overdiagnosis and overtreatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>This retrospective cohort study examines publicly reported industry-sponsored events in Australia from October 2011 to September 2015 for three conditions potentially subject to overdiagnosis and overtreatment: depression, osteoporosis and overactive bladder. We used a database of transparency reports to identify events with a focus on depression, osteoporosis and overactive bladder and compared these with other sponsored events. We hypothesised that companies marketing treatments for each condition would sponsor related events and that target audiences would mainly work in primary care, reflecting a broad patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Event and attendee characteristics, sponsoring companies, related marketed treatments, cost-effectiveness ratings and dispensing rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over the study period, we identified 1567 events focusing on depression, 1375 on osteoporosis and 190 on overactive bladder (total n=3132, with 96\u2009660 attendees). These events were attended by primary care doctors more often than sponsored events without a focus on these three conditions: relative risk (RR)=3.06 (95% CI 2.81 to 3.32) for depression, RR=1.48 (95% CI 1.41 to 1.55) for osteoporosis and RR=2.59 (95% CI 2.09 to 3.21) for overactive bladder. Servier, which markets agomelatine and AstraZeneca (quetiapine) sponsored 51.2% and 23.0% of depression events, respectively. Amgen and GlaxoSmithKline, which co-market denosumab, sponsored 49.5% of osteoporosis events and Astellas and Commonwealth Serum Laboratories (CSL) (mirabegron and solifenacin) sponsored 80.5% of overactive bladder events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This 4-year overview of industry-sponsored events on three overdiagnosed and overtreated conditions found that primary care clinicians were often targeted, dinner was often provided and that a few companies sponsored most events. In most cases, sponsors\u2019 products are not cost-effective choices for the specified condition. This pattern highlights the need for professional education to be free of commercial sponsorship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-019027","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T15:20:55Z","timestamp":1518535255000},"page":"e019027","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over\u00adactive bladder syndrome? An Australian cohort study"],"prefix":"10.1136","volume":"8","author":[{"given":"Barbara","family":"Mintzes","sequence":"first","affiliation":[{"name":"Charles Perkins Centre and Faculty of Pharmacy, University of Sydney, Camperdown, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swestika","family":"Swandari","sequence":"additional","affiliation":[{"name":"Makassar Health Training Centre, Ministry of Health, Makassar, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre and Faculty of Pharmacy, University of Sydney, Camperdown, NSW, Australia"},{"name":"Centre for Research in Medical Pharmacology, University of Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quinn","family":"Grundy","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre and Faculty of Pharmacy, University of Sydney, Camperdown, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Moynihan","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Bero","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre and Faculty of Pharmacy, University of Sydney, Camperdown, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"key":"2025121603352345000_8.2.e019027.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39496.430336.DB"},{"key":"2025121603352345000_8.2.e019027.2","first-page":"16504","article-title":"Is continuing medical education a drug-promotion tool?: no","volume":"532","author":"Marlow","year":"2007","journal-title":"Can Fam Physician"},{"key":"2025121603352345000_8.2.e019027.3","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2014-102596"},{"key":"2025121603352345000_8.2.e019027.4","unstructured":"Fauber J , Jones C , Fiore K . Slippery slope: testosterone muscles its way to profits. Medpage Today 2015. http:\/\/www.medpagetoday.com\/special-reports\/slipperyslope\/54156 (accessed 17 Jan 2017)."},{"key":"2025121603352345000_8.2.e019027.5","first-page":"694700","article-title":"Industry involvement in continuing medical education: time to say no","volume":"60","author":"Spithoff","year":"2014","journal-title":"Can Fam Physician"},{"key":"2025121603352345000_8.2.e019027.6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archinternmed.2012.3319","article-title":"Overdiagnosis of disease: a modern epidemic","volume":"172","author":"Hoffman","year":"2012","journal-title":"Arch Intern Med"},{"key":"2025121603352345000_8.2.e019027.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7342.886"},{"key":"2025121603352345000_8.2.e019027.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3502"},{"key":"2025121603352345000_8.2.e019027.9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.18773\/austprescr.2016.049","article-title":"Improving transparency in the pharmaceutical industry","volume":"39","author":"Monk","year":"2016","journal-title":"Aust Prescr"},{"key":"2025121603352345000_8.2.e019027.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000128","article-title":"Mandatory disclosure of pharmaceutical industry-funded events for health professionals","volume":"6","author":"Robertson","year":"2009","journal-title":"PLoS Med"},{"key":"2025121603352345000_8.2.e019027.11","unstructured":"Medicines Australia. Code of Conduct. 18th edn, 2015. https:\/\/medicinesaustralia.com.au\/wp-content\/uploads\/sites\/52\/2010\/01\/20150617-PUB-Code-Edition-18-FINAL.pdf"},{"key":"2025121603352345000_8.2.e019027.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016701","article-title":"Pharmaceutical industry-funded events for health professionals: an analysis of data released under Australian transparency rules","volume":"7","author":"Fabbri","year":"2017","journal-title":"BMJ Open"},{"key":"2025121603352345000_8.2.e019027.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f7140"},{"key":"2025121603352345000_8.2.e019027.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2088"},{"key":"2025121603352345000_8.2.e019027.15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.eururo.2011.12.013","article-title":"Does the imprecise definition of overactive bladder serve commercial rather than patient interests?","volume":"61","author":"Tikkinen","year":"2012","journal-title":"Eur Urol"},{"key":"2025121603352345000_8.2.e019027.16","unstructured":"AMH. Australian Medicines Handbook. Adelaide, Australia: AMH, 2016."},{"key":"2025121603352345000_8.2.e019027.17","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2014.05.140038"},{"key":"2025121603352345000_8.2.e019027.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60879-5"},{"key":"2025121603352345000_8.2.e019027.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3445"},{"key":"2025121603352345000_8.2.e019027.20","unstructured":"Organisation for Economic Cooperation and Development (OECD). Health at a Glance 2015: how does Australia compare? https:\/\/www.oecd.org\/australia\/Health-at-a-Glance-2015-Key-Findings-AUSTRALIA.pdf (accessed 16 Jan 2017)."},{"key":"2025121603352345000_8.2.e019027.21","unstructured":"Elliott C , Coat W , Hat B . Adventures on the dark side of medicine. Boston, MA, USA: Beacon Press, 2010."},{"key":"2025121603352345000_8.2.e019027.22","unstructured":"Mintzes B , doctor\u2019 \u2018Ask your . \u2018Ask your doctor\u2019. Women and direct to consumer advertising. In: Ford AR , Sabil D , eds. The push to prescribe: women and Canadian drug policy. Toronto: Women\u2019s Press, 2010:15\u201346."},{"key":"2025121603352345000_8.2.e019027.23","unstructured":"QuintilesIMS. Quetiapine Fumarate unit sales in Australia, 2012 to 2015. Data provided to authors on request by QuintilesIMS. 2016."},{"key":"2025121603352345000_8.2.e019027.24","unstructured":"Pharma Dispatch. Actavis takes back Actonel. 2014. https:\/\/pharmadispatch.com\/news\/actavis-takes-back-actonel (accessed 9 Jan 2017)."},{"key":"2025121603352345000_8.2.e019027.25","unstructured":"Pharmaceutical Benefits Scheme. Australian Department of Health. ASM_Table_1. Australian Statistics on Medicine. 2012 to 2015. 2016. https:\/\/www.pbs.gov.au\/info\/browse\/statistics (accessed 25 Jan 2017)."},{"key":"2025121603352345000_8.2.e019027.26","first-page":"144","article-title":"Pour Mieux Soigner: des m\u00e9dicaments \u00e0 \u00e9carter: bilan 2015","volume":"35","author":"Prescrire Editorial Staff","year":"2015","journal-title":"La Revue Prescrire"},{"key":"2025121603352345000_8.2.e019027.27","unstructured":"Anonymous. Worse than first-line antidepressants, up to 15-fold more expensive, and a worrying hepatic safety profile. Drug assessment report drug and therapeutics bulletin of navarre. 2010. DAR no. 3 http:\/\/www.navarra.es\/home_en\/Temas\/Portal+de+la+Salud\/Profesionales\/Documentacion+y+publicaciones\/Publicaciones+tematicas\/Medicamento\/FET\/2010\/DAR+No+3+Agomelatine.htm"},{"key":"2025121603352345000_8.2.e019027.28","doi-asserted-by":"crossref","unstructured":"Komossa K , Depping AM , Gaudchau A , et al . Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010;12. CD008121.doi:10.1002\/14651858.CD008121.pub2","DOI":"10.1002\/14651858.CD008121.pub2"},{"key":"2025121603352345000_8.2.e019027.29","unstructured":"Therapeutics Initiative. Antipsychotics should not be used for non-psychotic depression. 2015. Therapeutics Letter 95 http:\/\/www.ti.ubc.ca\/2015\/09\/30\/antipsychotics-should-not-be-used-for-non-psychotic-depression\/ (accessed 16 Jan 2017)."},{"key":"2025121603352345000_8.2.e019027.30","first-page":"105","article-title":"Towards better patient care: drugs to avoid in 2016","volume":"25","author":"Prescrire Editorial Staff","year":"2016","journal-title":"Prescrire Int"},{"key":"2025121603352345000_8.2.e019027.31","unstructured":"McColl G . Chair, drug utilisation sub committee. Drug utilisation committee outcome statement 29-30 september 2016. Canberra, Australia: Pharmaceutical Benefits Advisory Committee, Pharmaceutical Benefits Service, 2016. http:\/\/www.pbs.gov.au\/industry\/listing\/elements\/dusc-meetings\/dos\/dusc-dos-sep-2016.pdf"},{"key":"2025121603352345000_8.2.e019027.32","unstructured":"Therapeutics Initiative. Are claims for newer overactive bladder drugs warranted? 2015. Therapeutics Letter 93 http:\/\/www.ti.ubc.ca\/2015\/04\/22\/are-claims-for-newer-drugs-for-overactive-bladder-warranted\/ (accessed 26 Jan 2017)."},{"key":"2025121603352345000_8.2.e019027.33","unstructured":"Medicines and Health Products Regulatory Agency. Mirabegron (Betmiga): risk of severe hypertension and associated cerebrovascular and cardiac events. Drug Safety Update. 2015. https:\/\/www.gov.uk\/drug-safety-update\/mirabegron-betmiga-risk-of-severe-hypertension-and-associated-cerebrovascular-and-cardiac-events (accessed 20 Jan 2017)."},{"key":"2025121603352345000_8.2.e019027.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050001"},{"key":"2025121603352345000_8.2.e019027.35","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2010.199844"},{"key":"2025121603352345000_8.2.e019027.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.2.252"},{"key":"2025121603352345000_8.2.e019027.37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025121603352345000_8.2.e019027.38","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00008"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-019027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:35:31Z","timestamp":1765884931000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-019027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,13]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/bmjopen-2017-019027"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-019027","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}